Autologous activated macrophages (MAK™) coated ex vivo with humanized anti‐CD20 monoclonal antibodies can eradicate minimal residual disease in chronic lymphocytic leukaemia in clinical response

L. Sutton,D. Chaoui,B. Cazin,N. Azar,M. Chokri,J. Romet‐Lemonne,K. Maloum

DOI: https://doi.org/10.1111/j.1365-2141.2008.07272.x

2008-09-01

British Journal of Haematology

Abstract:Heavily pretreated chronic lymphocytic leukaemia (CLL) is associated with poor survival, as responses to the last treatment received are short-lived. The response duration correlates with the quality of remission, i.e. the level of persistent minimal residual disease (MRD) (Brugiatelli et al, 1997). We sought to improve the response duration by reducing MRD in such heavily treated patients achieving a new response. We therefore conducted a phase II trial of autologous activated macrophages (MAKs) coated with a humanized anti-CD20 antibody (rituximab), focusing on its safety and its capacity to eradicate MRD. Ten patients with Matutes score 5 CLL were enrolled. Five of the seven patients tested had wild-type IGHV (Table I). The patients had received between 2 and 6 previous lines (median 4) of chemotherapy, including at least one fludarabine-based regimen. Moreover, seven patients had been autografted after conditioning with total body irradiation and cyclophosphamide. Before inclusion in the study all the patients were treated until they reached their best possible response, based on the National Cancer Institute Working Group (NCI-WG) criteria. At inclusion, six patients were in complete remission (CR) and four had a partial response (PR). All the patients had MRD (presence of residual leukaemic cells), as demonstrated with a 4-colour phenotypic assay and polymerase chain reaction (PCR) amplification of the clonal immunoglobulin gene. Patients’ peripheral blood mononuclear cells (PBMC; 10) were isolated with a COBE Spectra device. Macrophages were produced from the PBMC with the MAK cell processor (Immuno-Design-Molecules, Paris, France) (Goxe et al, 1998). After 6 d of culture, interferon-c (Boehringer Ingelheim, France) was added at a concentration of 250 IU/ml to activate macrophages. On day 7, MAKs were purified by elutriation (B. Braun, France) and resuspended in 200 ml of serum albumin in the presence of 2Æ5 mg of rituximab (Roche, Basel, Switzerland). The number of MAKs to be reinfused was based on previously published experience (Faradji et al, 1991). The dose of rituximab (2Æ5 mg) was calculated in order to saturate immunoglobulin constant-region-fragment cell-surface receptors (FcR) of MAKs. Six infusions of MAKs/anti-CD20 were planned at one-week intervals. The primary endpoint was a decrease in MRD, as shown by a negative four-colour flow cytometric immunophenotype (Maloum et al, 2002) and confirmed by clone-specific PCR (cPCR).